NADAC acquisition cost data for LYBALVI 15-10 MG TABLET. This is a brand-name medication — generic alternatives may be available at lower prices.
| NDC | NADAC/Unit | Effective Date | Type |
|---|---|---|---|
| 65757065342 | $46.76 | 2022-11-11 | Rx |
| 65757065344 | $46.76 | 2022-11-11 | Rx |
| 65757065342 | $46.76 | 2022-11-11 | Rx |
| 65757065344 | $46.76 | 2022-11-11 | Rx |
| 65757065342 | $46.76 | 2022-11-11 | Rx |
| 65757065344 | $46.76 | 2022-11-11 | Rx |
| 65757065342 | $46.76 | 2022-11-11 | Rx |
| 65757065344 | $46.76 | 2022-11-11 | Rx |
| 65757065342 | $46.76 | 2022-11-11 | Rx |
| 65757065344 | $46.76 | 2022-11-11 | Rx |
Generic: Olanzapine/Samidorphan Malate | Manufacturer: Overall
| Year | Total Spending | Claims | Beneficiaries | Cost/Unit |
|---|---|---|---|---|
| 2019 | N/A | N/A | N/A | N/A |
| 2020 | N/A | N/A | N/A | N/A |
| 2021 | $1.7M | 1,163 | 766 | $48.43 |
| 2022 | $39.2M | 26,490 | 5,745 | $49.40 |
| 2023 | $90.0M | 56,531 | 9,246 | $52.66 |
| State | Total Cost | Claims | Beneficiaries |
|---|---|---|---|
| California | $8.6M | 5,427 | 912 |
| Texas | $7.2M | 4,298 | 747 |
| Florida | $6.3M | 3,858 | 678 |
| New York | $5.0M | 3,120 | 572 |
| Missouri | $4.2M | 2,799 | 389 |
| Ohio | $4.2M | 2,688 | 446 |
| North Carolina | $3.4M | 2,097 | 371 |
| Iowa | $3.2M | 2,136 | 296 |
| Pennsylvania | $3.1M | 1,944 | 316 |
| Michigan | $2.7M | 1,747 | 294 |
| Wisconsin | $2.6M | 1,701 | 274 |
| Indiana | $2.6M | 1,676 | 288 |
| Minnesota | $2.3M | 1,375 | 208 |
| Illinois | $2.2M | 1,379 | 243 |
| Louisiana | $1.9M | 1,148 | 209 |
| Alabama | $1.9M | 1,128 | 190 |
| Oklahoma | $1.8M | 1,142 | 179 |
| Tennessee | $1.8M | 1,102 | 217 |
| Georgia | $1.8M | 1,083 | 197 |
| New Jersey | $1.7M | 1,102 | 179 |
| Kentucky | $1.6M | 993 | 192 |
| Arizona | $1.5M | 1,022 | 171 |
| Massachusetts | $1.4M | 846 | 165 |
| Connecticut | $1.3M | 752 | 116 |
| Virginia | $1.3M | 774 | 154 |
| Nebraska | $1.2M | 830 | 132 |
| Washington | $1.2M | 747 | 123 |
| Kansas | $1.1M | 765 | 121 |
| South Carolina | $1.1M | 677 | 122 |
| Maryland | $1.0M | 620 | 108 |
| Colorado | $875.5K | 534 | 96 |
| Oregon | $786.3K | 495 | 92 |
| Delaware | $778.7K | 492 | 74 |
| New Hampshire | $620.0K | 435 | 63 |
| Idaho | $617.4K | 425 | 73 |
| Utah | $579.3K | 354 | 52 |
| Mississippi | $542.1K | 311 | 63 |
| South Dakota | $518.2K | 348 | 46 |
| New Mexico | $502.8K | 312 | 46 |
| Hawaii | $441.1K | 289 | 45 |
| Nevada | $410.6K | 230 | 47 |
| Arkansas | $404.6K | 241 | 52 |
| Maine | $379.9K | 225 | 35 |
| Rhode Island | $359.7K | 245 | 36 |
| West Virginia | $220.6K | 132 | 27 |
| District of Columbia | $178.6K | 110 | 19 |
| North Dakota | $159.7K | 98 | 18 |
| Wyoming | $153.6K | 98 | 15 |
| Montana | $74.2K | 47 | N/A |
| Alaska | $61.0K | 43 | N/A |
| Vermont | $31.5K | 19 | N/A |
| Armed Forces Pacific | $19.8K | 12 | N/A |
The DrugPricePeek editorial team aggregates and verifies drugs data from CMS NADAC & Medicare Part D. Every statistic on this site is cross-referenced against the official source before publication, with quarterly re-verification cycles.
Read our full methodology or contact us with corrections.